Drug intelligence / Profile preview

ART-200

Development stage: Preclinical
Lead developer: Arum Therapeutics
Modality: Small Molecules

Overview

ART-200 is a preclinical-stage small molecule pan-RAS inhibitor being developed by Arum Therapeutics. It is designed to target multiple isoforms and mutations of the RAS GTPase family, including KRAS, NRAS, and HRAS. By inhibiting RAS-mutant biology, ART-200 aims to overcome cancer cell resistance and suppress proliferation in various solid tumors driven by RAS mutations. The program is currently in the hit-to-lead phase of development, focusing on addressing the therapeutic challenges posed by the broad spectrum of RAS mutations in oncology.

Other names: ART-200ART200ART 200

Targets

HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)

Beyond the preview

Go deeper on ART-200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART-200.

Explore the full profile